Horizon Pharma PLC (HZNP) Stock Price Up 6.4%
Shares of Horizon Pharma PLC (NASDAQ:HZNP) rose 6.4% during trading on Monday . The company traded as high as $13.51 and last traded at $13.49. Approximately 3,848,083 shares were traded during mid-day trading, an increase of 0% from the average daily volume of 3,836,240 shares. The stock had previously closed at $12.68.
A number of research firms recently weighed in on HZNP. ValuEngine downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub raised Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald set a $13.00 price objective on Horizon Pharma PLC and gave the company a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and set a $14.00 price objective on shares of Horizon Pharma PLC in a report on Friday, July 14th. Finally, Piper Jaffray Companies set a $18.00 price objective on Horizon Pharma PLC and gave the company a “buy” rating in a report on Sunday, September 10th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $18.00.
The firm’s 50-day moving average is $12.88 and its 200 day moving average is $12.74. The company’s market cap is $2.12 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.12 by $0.29. The business had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.56 earnings per share. On average, equities analysts anticipate that Horizon Pharma PLC will post $1.07 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in HZNP. Morgan Stanley grew its stake in shares of Horizon Pharma PLC by 59.7% in the 1st quarter. Morgan Stanley now owns 1,422,666 shares of the biopharmaceutical company’s stock worth $21,027,000 after buying an additional 531,882 shares during the last quarter. Russell Investments Group Ltd. increased its position in Horizon Pharma PLC by 82.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 69,626 shares in the last quarter. Neuberger Berman Group LLC bought a new position in Horizon Pharma PLC during the 2nd quarter valued at approximately $7,147,000. US Bancorp DE increased its position in Horizon Pharma PLC by 1.2% during the 1st quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 368 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Horizon Pharma PLC by 19.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock valued at $10,866,000 after buying an additional 150,850 shares in the last quarter. Hedge funds and other institutional investors own 82.33% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.